Inner Mongolia University Research Center for Glycochemistry of Characteristic Medicinal Resources, School of Chemistry and Chemical Engineering, Inner Mongolia University, Hohhot, 010021, PR China.
Institute of Integrative Biosciences, CECOS University of IT and Emerging Sciences, Peshawar, KPK, Pakistan; Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai, 200241, PR China.
Eur J Med Chem. 2021 Nov 15;224:113689. doi: 10.1016/j.ejmech.2021.113689. Epub 2021 Jul 7.
Triple-negative-breast cancer (TNBC) and HER-2 enriched positive aggressive types of breast cancer and are highly metastatic in nature. Anticancer agents those target TNBC and HER-2 enriched positive breast cancers are considered important in the field of breast cancer research. In search of the effective anticancer agents, we synthesized Pt(II) complexes to target these cancers. Platinum complexes (C1-C8) were prepared in single step by the reaction of commercially available KPtCl with the readily prepared ligands (L1-L8). All these compounds were characterized successfully by different spectroscopic and spectrophotometric analyses. Structures of C1, C3 and C8 were characterized by single crystal X-ray analysis that confirmed the exact chelation mode of the SNO-triply coordinated ligand. All these complexes inhibited the in vitro growth of MCF-7 (luminal-like), MDA-MB-231 (TNBC) and SKBR3 (HER-2 enriched) breast cancer cells. C1, C3 and C7 induced cell death and suppressed the clonogenic potential of these cancer cells. Importantly, C1, C3 and C7 showed potentials to suppress cancer stem cells/mammosphere formation and cell migration ability of MDA-MB-231 and SKBR3 breast cancer cells. These complexes also induced cellular senescence in MDA-MB-231 and SKBR3 cells, thus suggesting a cell retardation mechanism. Similarly, these complexes induced DNA damage by activating p-H2AX expression and promoted autophagy via ATG3/LC3B axis activation in MDA-MB-231 and SKBR3 cells. Furthermore, these complexes decreased the expression of oncogenic proteins such as BCL2 and cylin-D1 those are involved in cancer cell survival and cell cycle progression. To further gain insight, we found that C1 and C7 targeted glycolytic pathways by regulating PKM and LDHA expression, which are involved in glycolysis. Moreover, C1 and C7 suppressed the formation of ATP production that is required for cancer cell growth. Taken together, the easy synthesis and biological assays results point towards the importance of these complexes in MDA-MB-231 (TNBC) and SKBR3 (HER-2 enriched) breast cancer cells by targeting multiple signaling pathways those are considered important during breast cancer progression. This study produces bases for further deeper in vitro or in vivo study that could lead to the effective breast cancer agents which we are working on.
三阴性乳腺癌(TNBC)和 HER-2 阳性侵袭性乳腺癌具有高度转移性。针对 TNBC 和 HER-2 阳性乳腺癌的抗癌药物在乳腺癌研究领域被认为是重要的。为了寻找有效的抗癌药物,我们合成了针对这些癌症的铂(II)配合物。通过市售的 KPtCl 与易于制备的配体(L1-L8)的反应,一步合成了铂配合物(C1-C8)。所有这些化合物都通过不同的光谱和分光光度分析成功地进行了表征。C1、C3 和 C8 的结构通过单晶 X 射线分析进行了表征,证实了 SNO-三配位配体的精确螯合模式。所有这些配合物都抑制了 MCF-7(管腔样)、MDA-MB-231(TNBC)和 SKBR3(HER-2 阳性)乳腺癌细胞的体外生长。C1、C3 和 C7 诱导细胞死亡并抑制这些癌细胞的集落形成能力。重要的是,C1、C3 和 C7 显示出抑制 MDA-MB-231 和 SKBR3 乳腺癌细胞中的癌症干细胞/类器官形成和细胞迁移能力的潜力。这些配合物还诱导 MDA-MB-231 和 SKBR3 细胞发生细胞衰老,从而提示一种细胞阻滞机制。同样,这些配合物通过激活 p-H2AX 表达诱导细胞 DNA 损伤,并通过激活 ATG3/LC3B 轴促进 MDA-MB-231 和 SKBR3 细胞中的自噬。此外,这些配合物降低了参与癌细胞存活和细胞周期进展的癌蛋白 BCL2 和 cylin-D1 的表达。为了进一步深入了解,我们发现 C1 和 C7 通过调节参与糖酵解的 PKM 和 LDHA 的表达来靶向糖酵解途径。此外,C1 和 C7 抑制了癌细胞生长所需的 ATP 产生的形成。总之,这些配合物的简单合成和生物学测定结果表明,它们在 MDA-MB-231(TNBC)和 SKBR3(HER-2 阳性)乳腺癌细胞中通过靶向多个信号通路具有重要意义,这些信号通路在乳腺癌进展过程中被认为是重要的。这项研究为进一步的体外或体内研究奠定了基础,这可能会导致我们正在研究的有效的乳腺癌药物。